Mirae Asset Global Investments Co. Ltd. Buys 13,358 Shares of Sanofi (NASDAQ:SNY)

Mirae Asset Global Investments Co. Ltd. grew its position in Sanofi (NASDAQ:SNY - Free Report) by 124.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,131 shares of the company's stock after acquiring an additional 13,358 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Sanofi were worth $1,344,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Sowell Financial Services LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $328,000. Farther Finance Advisors LLC lifted its position in shares of Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after buying an additional 2,476 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in shares of Sanofi by 1.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company's stock worth $1,848,000 after buying an additional 318 shares during the period. Geode Capital Management LLC lifted its position in shares of Sanofi by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 257,655 shares of the company's stock worth $12,427,000 after buying an additional 2,917 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its position in shares of Sanofi by 3.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 8,640 shares of the company's stock worth $479,000 after buying an additional 298 shares during the period. Institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

SNY has been the subject of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Stock Down 0.9%

Shares of NASDAQ:SNY traded down $0.43 during midday trading on Friday, reaching $48.89. The company had a trading volume of 1,555,600 shares, compared to its average volume of 2,340,767. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The business's 50 day moving average price is $50.61 and its 200 day moving average price is $52.05. The stock has a market cap of $119.89 billion, a PE ratio of 17.46, a P/E/G ratio of 1.05 and a beta of 0.48. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business's revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.78 earnings per share. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.